FH:CC News and Press, FILAMENT HEALTH CORP. From 01/10/23

Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses Canada NewsWire New venture aligns with Jaguar's mental health Entheogen Therapeuti...

FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD OF DIRECTORS Canada NewsWire VANCOUVER, BC , Dec. 30, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychede...

VANCOUVER, BC / ACCESSWIRE / December 19, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Trillion Energy, Silver Bullet Mines, Clean Air Metals, Mullen Group and Psyence Group discussing their latest news. The Power Play by The Market Herald provides...

NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on...

VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc ( CSE:PSYG |...

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE FOR PALLIATIVE CARE Canada NewsWire The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament's natural psilocybin drug candidate PEX010 25mg ...

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be ...

VANCOUVER, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Filament Health (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical stage natural psychedelic drug development company, today announced that Benjamin Lightburn, CEO and Co-Founder, will present live at VirtualInvestorConferences.com...

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES Canada NewsWire Filament's industry-leading IP portfolio now consists of ten patents for methods of extracting and standardizing natural psychedelic compounds VANCOUVER, BC , Nov. 30, 2022 /CNW/...

FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Canada NewsWire CAMH to use Filament's natural psilocybin drug candidate for a clinical trial studying treatment-resistant depression VANCOUVER, BC , ...